🇺🇸 FDA

Company profile · Sponsor

MoonLake

MoonLake Immunotherapeutics

MLTX · NYSE pharma ZUG, V8, USA
Pipeline
13
Drugs
0
Patents
0

Quick answer

MoonLake (MLTX) is a pharma company. headquartered in ZUG, V8, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker MLTX
Exchange NYSE
Company type pharma
Headquarters ZUG, V8, USA
SEC CIK 0001821586

Pipeline (13)

Search pipeline →

  1. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  2. Sonelokimab

    MoonLake

    Hidradenitis Suppurativa

    phase 3 small molecule active

    4 trials

  3. Sonelokimab

    MoonLake

    psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  4. Sonelokimab

    MoonLake

    Hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  5. Sonelokimab

    MoonLake

    Arthritis, Psoriatic

    phase 3 small molecule active

    4 trials

  6. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  7. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. 68Ga-FAPI-46, Sonelokimab

    MoonLake

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  10. Sonelokimab

    MoonLake

    axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  11. Sonelokimab

    MoonLake

    Palmoplantar Pustulosis

    phase 2 small molecule active

    1 trial

  12. Sonelokimab (M1095)

    MoonLake

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  13. Sonelokimab

    MoonLake

    Relative Bioequivalence

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is MoonLake?

MoonLake (MLTX) is a pharma company. headquartered in ZUG, V8, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does MoonLake sponsor?

We track 13 ClinicalTrials.gov-linked programs for MoonLake, including Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does MoonLake company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.